SARS-CoV-2 variants from mink evade inhibition by antibodies
Descrição
It has been known for about a year that minks can become infected with SARS-CoV-2. The virus had been transmitted from humans to farmed mink and mutated in infected animals. Mutations were acquired in the spike protein, which is crucial for the entry of the virus into host cells and represents the central point of attack for antibodies. These SARS-CoV-2 variants from mink were transmitted back to humans, raising concerns that minks could be a continuing source of infection of humans with SARS-CoV-2 variants with altered biological properties. Researchers at the German Primate Center (DPZ) - Leibniz Institute for Primate Research in Göttingen, Germany, have now shown that an antibody used for COVID-19 therapy is unable to effectively inhibit SARS-CoV-2 harboring a spike mutation acquired in minks. In addition, the mutation reduced the inhibition of the virus by antibodies produced in SARS-CoV-2 infected humans. These results show that SARS-CoV-2 can acquire mutations in minks that may reduce control of the virus by the human immune system. The study and findings have been published in Cell Reports.
A bioluminescent and homogeneous SARS-CoV-2 spike RBD and hACE2 interaction assay for antiviral screening and monitoring patient neutralizing antibody levels
Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity
Microorganisms, Free Full-Text
The alpha/B.1.1.7 SARS-CoV-2 variant exhibits significantly higher affinity for ACE-2 and requires lower inoculation doses to cause disease in K18-hACE2 mice
Neutralizing Antibodies to SARS‐CoV‐2 Selected from a Human Antibody Library Constructed Decades Ago - Qiang - 2022 - Advanced Science - Wiley Online Library
Molecular Basis of Mink ACE2 Binding to SARS-CoV-2 and Its Mink-Derived Variants
Emerging SARS-CoV-2 Variants: Genetic Variability and Clinical Implications
SARS-CoV-2 variants: A double-edged sword? - Manasi P Jogalekar, Anurag Veerabathini, Prakash Gangadaran, 2021
Uncovering a conserved vulnerability site in SARS‐CoV‐2 by a human antibody
de
por adulto (o preço varia de acordo com o tamanho do grupo)
